Stephen From


Challenges With Addressing Neurodegeneration in Poststroke Patients: Stephen From

The chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]

Ye Vivian Liang, MD, PhD


Planning Spasticity Treatment Based on Patient Goals

A panel of experts discuss designing treatment plans based on patient goals.

Hermona Soreq, PhD


Role of Cholinergic Transcripts in Sex-Specific Declines of Alzheimer Disease: Hermona Seroq, PhD

The professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]

Ihtsham ul Haq, MD, FAAN


Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

Jonathan Graff-Radford, MD


Jonathan Graff-Radford, MD: Blood Tests as a Diagnostic Innovation in Alzheimer Disease

The neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.

Spencer Hutto, MD


CNS Demyelination and Autoimmune Neurology: Spencer Hutto, MD

The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.

Elias Kouchakji, MD


Elias Kouchakji, MD: Investigating Pamrevlumab for DMD in Phase 3 LELANTOS Study

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.

Vincent Martin, MD


Weighing Approaches on Preventive Use, Medication Overuse in Chronic Migraine: Vincent Martin, MD

The president of the National Headache Foundation discussed whether switching or continuing preventive medications has a benefit in patients who have chronic migraine with medication overuse. [WATCH TIME: 4 minutes]

Alexander Merkler, MD, MS


Future Research Regarding Anticoagulant Use in Reducing Recurrent Stroke: Alexander Merkler, MD, MS

The assistant professor of neurology at Weill Cornell Medicine discussed his future aspirations to uncover more about the beneficial effects of anticoagulants in reducing recurrent stroke. [WATCH TIME: 3 minutes]

Shafali Jeste, MD


Current Roadblocks Toward Expanding Gene Therapy Across Pediatric Neurology: Shafali Jeste, MD

The chief of neurology and co-director of the Neurological Institute at the Children’s Hospital Los Angeles described some of the major resource and policy-level barriers for gene therapy in pediatric neurological conditions. [WATCH TIME: 6 minutes]

Amynah Pradhan, PhD


Shaping the Future of Medical Research Using Insights From the Headache Community: Amynah Pradhan, PhD

The associate professor of psychiatry at the University of Illinois at Chicago talked about the importance of diverse insight and perspectives from the headache community in shaping medical research priorities. [WATCH TIME: 3 minutes]

Jason Sico, MD, MHS


AUPN 2022 Veterans Health Administration Workshop

Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]

Ali Rezai, MD


Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD

The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]

Bryan Roth, MD, PhD


Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]

Ali Habib, MD


Improving Patient Communication in MG

Expert neurologists share thoughts on how to improve patient/physician communication and how listening to the patient needs will aid in managing MG.

AJ Joshi, MD


Next Steps for ATA188, Research Related to EBV and Multiple Sclerosis: AJ Joshi, MD

The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]

Nathaniel Schuster, MD


Future Research on Cannabis Use to Treat Migraine: Nathaniel Schuster, MD

The pain management specialist and headache neurologist at the University of California San Diego Center for Pain Medicine discussed the different forms of cannabis and the need to conduct larger, multicenter studies to better understand its effects in migraine. [WATCH TIME: 3 minutes]

Carla LoPinto-Khoury, MD, FAES


Lifting Barriers to Equitable Care in Epilepsy

Four neurologists treating patients with epilepsy share their experience in and out of the clinic tackling issues of access for their patients.

Rebecca Erwin Wells, MD, MPH


The Changing Landscape of Preventative Migraine Treatments

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.

Douglas J. Gelb, MD, PhD


AUPN Leadership Minute Episode 9: Engaging Medical Students in Neurology – Part 2

Episode 9 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the Veterans Health Administration; and Douglas J. Gelb, MD, PhD, of the University of Michigan [WATCH TIME: 5 minutes]

Rana K. Zabad, MD, FAAN


The Evolving Diagnostic Criteria for Multiple Sclerosis

Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.

John Chen, MD, PhD


Building a Greater Understanding for NMOSD Treatments, Neurodegeneration: John Chen, MD, PhD

The neuroophtalmologist at Mayo Clinic detailed improvements in prescribing methods for NMOSD treatments and the conversations surrounding reversing neurodegeneration. [WATCH TIME: 3 minutes]

Bernd C. Kieseier, MD


The Unresolved Bottleneck of Accessing Care for Mental Health in MS: Bernd C. Kieseier, MD

The global program head of the development unit for neuroscience at Novartis talked about the evolving landscape of mental health care for multiple sclerosis including the accessibility barrier that remains for patients in many regions. [WATCH TIME: 4 minutes]

Frank Gleeson


Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson

The president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]

Ifrah Zawar, MD


Insights From Comprehensive Research on Epilepsy and Cognitive Decline: Ifrah Zawar, MD

The assistant professor of neurology at the University of Virginia talked about findings from a comprehensive study on epilepsy and mild cognitive impairment, which was recently presented at AES 2023. [WATCH TIME: 5 minutes]

Masashi Kitazawa, PhD


Air Pollution’s Impact on Cognitive Decline and the Neurotoxicity of Particulate Matter: Masashi Kitazawa, PhD

The associate professor of environmental and occupational Health at the University of California, Irvine, talked about the impact of concentrated particulate matter or air pollution on cognitive function in animal models. [WATCH TIME: 5 minutes]

Sana Somani, MD, MBBS


Preventing Secondary Stroke: Practical Application of Updated Guidelines

Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.

Diana Castro, MD


Challenges in Transitioning Care for Duchenne Muscular Dystrophy: Diana Castro, MD

The neuromuscular specialist at the Neurology & Neuromuscular Care Center discussed the pressing need to address the transition of care from pediatric to adult healthcare systems in Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]

Megan Iammarino, PT, DPT


Physical Therapy, Optimizing Function in Neuromuscular Diseases: Megan Iammarino, PT, DPT

The research physical therapist at Nationwide Children’s Hospital talked about the role of physical therapy in the changing landscape of care with neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 5 minutes]

Tyler Kaplan, MD


Bruton Tyrosine Kinase Inhibitors: A New Hope for the Management of Progression in MS?

Several therapies are progressing through the development pipeline and have shown promising data, setting up the multiple sclerosis treatment toolbox for possible expansion in coming years.

© 2024 MJH Life Sciences

All rights reserved.